7V3 Stock Overview
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cantargia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.29 |
| 52 Week High | kr0.52 |
| 52 Week Low | kr0.21 |
| Beta | 1.57 |
| 1 Month Change | 22.72% |
| 3 Month Change | -5.37% |
| 1 Year Change | -44.24% |
| 3 Year Change | -91.26% |
| 5 Year Change | -82.26% |
| Change since IPO | -81.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7V3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.6% | -0.2% | 0.5% |
| 1Y | -44.2% | -22.8% | 1.3% |
Return vs Industry: 7V3 underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: 7V3 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 7V3 volatility | |
|---|---|
| 7V3 Average Weekly Movement | 15.8% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7V3's share price has been volatile over the past 3 months.
Volatility Over Time: 7V3's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 22 | Goran Forsberg | www.cantargia.com |
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04 (Nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer and non-small cell lung cancer, as well as Phase Ib/II for the treatment of triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It is also developing CANxx, an IL1RAP-based antibody platform.
Cantargia AB (publ) Fundamentals Summary
| 7V3 fundamental statistics | |
|---|---|
| Market cap | €54.58m |
| Earnings (TTM) | -€23.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.3x
P/E RatioIs 7V3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7V3 income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr280.03m |
| Earnings | -kr280.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 21, 2024
| Earnings per share (EPS) | -1.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7V3 perform over the long term?
See historical performance and comparison